The Centers for Medicare & Medicaid Services (CMS), recently issued a press release calling for more development of innovative payment models for life-saving drugs, which could include outcomes-based pricing. The press release follows the recent approval of tisagenleclucel (Kymirah), a personalized genetically-modified autologous T cell immunotherapy for pediatric and young adult patients with leukemia.
“CMS congratulates all of the scientists and researchers involved in the development of Kymriah (tisagenlecleucel),” said CMS Administrator Seema Verma. “Innovations like this reinforce our belief that current healthcare payment systems need to be modernized in order to ensure access to new high-cost therapies, including therapies that have the potential to cure the sickest patients. Improving payment arrangements is a critical step towards fulfilling President Trump’s promise to lower the cost of drugs.”
According to CMS, they are working closely with stakeholders and state officials on developing these new payment methods and will be issuing future guidance to pharmaceutical manufacturers outlining how they can participate in this ongoing effort to manage the costs associated with new therapies.